Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04565821 · ClinicalTrials.gov registry record · NA

Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe

A NA study of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT04565821: Active NA study of Crohn Disease and Inflammatory Bowel Diseases, sponsored by Massachusetts General Hospital.

NCT04565821 is a NA study of Crohn Disease and Inflammatory Bowel Diseases that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 15 participants, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04565821, a NA study of Crohn Disease and Inflammatory Bowel Diseases, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability

Primary Outcome

Feasibility will be measured by the IPD probes ability to, accurately and in real-time, measure voltages that are consistent with literature for the tissue we are testing

Interventions

  • DEVICE IPD Probe via TNIT

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2020-11-12
Est. Completion 2028-04-30
Phase NA
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT04565821 still lists

NCT04565821 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 205-participant average among 71 other Crohn Disease trials with a reported enrollment target (93% lower).

The record links to 5 conditions, with Crohn Disease appearing as the primary indexed condition, and to 1 intervention - of which IPD Probe via TNIT is the first listed.

NCT04565821 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04565821 about?

NCT04565821 is a clinical study titled "Feasibility Study to Assess a Trans-nasal Intestinal Potential Difference Probe". The purpose of this study is to examine the feasibility of using a trans-nasal IPD probe as a measurement tool for gut permeability

What is the current status of trial NCT04565821?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2020-11-12. Estimated completion is 2028-04-30.

What conditions does trial NCT04565821 study?

This clinical trial studies the following conditions: Crohn Disease, Inflammatory Bowel Diseases, Inflammatory Disease, Permeability; Increased, Environmental Enteropathy.

What interventions are being tested in trial NCT04565821?

The interventions under investigation include: IPD Probe via TNIT (DEVICE).

Who is sponsoring clinical trial NCT04565821?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04565821 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Crohn Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04565821's enrollment target sits among peer trials

15 66th of 71 higher than 4 of 71 other Crohn Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Crohn Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04565821, the US trial registry maintained by the National Library of Medicine. NCT04565821 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.